Goldman Sachs
GMAB icon

Goldman Sachs’s Genmab GMAB Stock Holding History

Goldman Sachs’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$25M Sell
931,259
-402,044
-30% -$12M ﹤0.01% 2216
2025
Q4 		$41.1M Buy
1,333,303
+214,674
+19% +$6.69M 0.01% 1676
2025
Q3 		$34.3M Buy
1,118,629
+229,354
+26% +$5.59M ﹤0.01% 1748
2025
Q2 		$18.4M Buy
889,275
+180,924
+26% +$3.71M ﹤0.01% 2202
2025
Q1 		$13.9M Sell
708,351
-64,753
-8% -$1.36M ﹤0.01% 2384
2024
Q4 		$16.1M Sell
773,104
-52,042
-6% -$1.14M ﹤0.01% 2341
2024
Q3 		$20.1M Sell
825,146
-52,706
-6% -$1.41M ﹤0.01% 2079
2024
Q2 		$22.1M Buy
877,852
+222,506
+34% +$6.31M ﹤0.01% 1806
2024
Q1 		$19.6M Buy
655,346
+127,422
+24% +$3.74M ﹤0.01% 1853
2023
Q4 		$16.8M Sell
527,924
-108,410
-17% -$3.4M ﹤0.01% 2068
2023
Q3 		$22.4M Buy
636,334
+19,229
+3% +$733K ﹤0.01% 1692
2023
Q2 		$23.5M Sell
617,105
-192,064
-24% -$7.66M 0.01% 1715
2023
Q1 		$30.6M Buy
809,169
+83,576
+12% +$3.21M 0.01% 1438
2022
Q4 		$30.8M Sell
725,593
-13,676
-2% -$564K 0.01% 1573
2022
Q3 		$23.8M Buy
739,269
+228,563
+45% +$8.03M 0.01% 1711
2022
Q2 		$16.6M Sell
510,706
-454,462
-47% -$14.7M ﹤0.01% 2057
2022
Q1 		$34.9M Sell
965,168
-539,994
-36% -$18.5M 0.01% 1604
2021
Q4 		$59.5M Sell
1,505,162
-120,831
-7% -$5.04M 0.01% 1206
2021
Q3 		$71.1M Sell
1,625,993
-133,142
-8% -$5.98M 0.02% 983
2021
Q2 		$71.8M Sell
1,759,135
-19,360
-1% -$747K 0.02% 975
2021
Q1 		$58.4M Buy
1,778,495
+262,284
+17% +$9.86M 0.01% 1048
2020
Q4 		$61.6M Buy
1,516,211
+538,157
+55% +$20.1M 0.02% 965
2020
Q3 		$35.8M Buy
978,054
+9,318
+1% +$337K 0.01% 1261
2020
Q2 		$32.8M Buy
968,736
+762,210
+369% +$20.8M 0.01% 1290
2020
Q1 		$4.38M Buy
206,526
+106,437
+106% +$2.37M ﹤0.01% 2747
2019
Q4 		$2.23M Buy
100,089
+17,420
+21% +$380K ﹤0.01% 3570
2019
Q3 		$1.68M Buy
+82,669
New +$1.63M ﹤0.01% 3663

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Goldman Sachs's GMAB Position: Q1 2026 in Review

Goldman Sachs reduced its Genmab (GMAB) stake by 30% in Q1 2026, selling an estimated $12M and leaving 931,259 shares worth $25M. The position accounts for ﹤0.01% of the portfolio, ranked #2216.

Goldman Sachs first reported a position in GMAB in Q3 2019 and has held it in 27 quarters since. The position peaked at $71.8M in Q2 2021. 272 funds tracked by Wall St. Rank hold GMAB as of Q1 2026.

  • Goldman Sachs held 931,259 shares of Genmab worth $25M as of Q1 2026.
  • Goldman Sachs sold 402,044 Genmab shares in Q1 2026, an estimated $12M.
  • Genmab made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2216 holding.
  • Goldman Sachs first reported a position in Genmab in Q3 2019 and has held it in 27 quarters since.
  • Goldman Sachs's Genmab position peaked at $71.8M in Q2 2021.
  • 272 funds tracked by Wall St. Rank held Genmab as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.